Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1695234

registered interest
date	12/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	18214
answer	answer is ministerial correction date of answer 20/03/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).</p><p> </p><p>On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.</p><p> </p><p>Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 20/03/2024 17:11:23 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1694161

registered interest
date	06/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	17412
answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.</p><p> </p><p>The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 16:04:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1691367

registered interest
date	23/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department plans to take steps to ensure that every person with diabetes has access to medical technology that helps them manage their condition.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	15459
answer	answer is ministerial correction date of answer 29/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target.</p><p>In March 2023 the National Institute for Health and Care Excellence (NICE) recommended that insulin dependent patients with type 2 diabetes should also benefit from flash or continuous glucose monitoring devices. We are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p><p>On 19 December 2023 the NICE published its final recommendation on the hybrid closed loop system. The NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be the first to be offered a hybrid closed loop system, as part of a five-year roll-out plan. Access to hybrid closed loop systems will be through a five-year phased roll out, in line with NHS England’s implementation plans.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/02/2024 14:08:08 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1675649

registered interest
date	05/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	5381
answer	answer is ministerial correction date of answer 11/12/2023 answer text <p>We have no specific plans to make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease. However, in England, NHS England is working with front-line clinical experts, patient representative groups and leading charities, including Crohn’s and Colitis UK, to improve diagnosis and treatment of inflammatory bowel disease (IBD). This includes a new IBD RightCare scenario, which, when published, will set out high-quality joined-up care at every point of the patient journey, as well as data packs for local commissioners.</p><p>In addition, the Getting it Right First Time specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country. Information on trends in the incidence rates of Crohn’s disease and ulcerative colitis is not held.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 5382 question first answered 11/12/2023 17:45:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1675650

registered interest
date	05/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data her Department holds on trends in the incidence rates of (a) Crohn’s and (b) Ulcerative Colitis.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	5382
answer	answer is ministerial correction date of answer 11/12/2023 answer text <p>We have no specific plans to make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease. However, in England, NHS England is working with front-line clinical experts, patient representative groups and leading charities, including Crohn’s and Colitis UK, to improve diagnosis and treatment of inflammatory bowel disease (IBD). This includes a new IBD RightCare scenario, which, when published, will set out high-quality joined-up care at every point of the patient journey, as well as data packs for local commissioners.</p><p>In addition, the Getting it Right First Time specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country. Information on trends in the incidence rates of Crohn’s disease and ulcerative colitis is not held.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 5381 question first answered 11/12/2023 17:45:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1672411

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes and Obesity: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department has taken to ensure that second generation GLP-1 weight management medications are being (a) sold and (b) marketed according to their licence specifications.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	3292
answer	answer is ministerial correction date of answer 01/12/2023 answer text <p>The Department and the Medicines and Healthcare products Regulatory Agency (MHRA) are members of the GLP1-RA Incident Management Team. Risk management in relation to the advertising and sale of these medicinal products is a standing item for discussion.</p><p>MHRA is obliged to consider complaints received about the advertisement of prescription-only medicines (POMs) to the public. Advertising investigations are carried out on a case-by-case basis, having regard to the circumstances of the particular case. Completed advertising investigations leading to correction of advertising materials are available at the following link:</p><p><a href="https://www.gov.uk/government/collections/advertising-investigations-by-mhra" target="_blank">https://www.gov.uk/government/collections/advertising-investigations-by-mhra</a></p><p>MHRA works closely with other regulators to help ensure that the public are protected from the advertising of POMs. A joint enforcement operation is in place with the Advertising Standards Authority to take targeted action against weight-loss treatment providers who use social media to promote POMs.</p><p>MHRA takes proportionate action, on a case-by-case basis, to enforce the Human Medicines Regulations 2012 in respect of the advertisement, sale, and supply of second-generation glucagon-like peptide 1 weight management medications. In cases of serious non-compliance, this can include undertaking formal criminal investigations and, where appropriate and evidentially supported, prosecution through the Crown Prosecution Service.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 3294 question first answered 01/12/2023 14:01:16 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1672414

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes and Obesity: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to prevent second generation GLP-1 weight management medications being available for purchase online without prescription.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	3293
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) enforces the Human Medicines Regulations 2012 on behalf of the Secretary of State for Health and Social Care. Buying any medicinal product, including second generation glucagon-like peptide 1 weight management medications, from illegally trading online suppliers significantly increases the risk of getting a product which is either falsified or not licensed for use in the United Kingdom. The MHRA continues to work with social media and online sales platforms to build strong partnerships to identify and quickly remove illegal medicines from sale and to identify those unlawfully trading in medicines. We work with partners to remove web content where we can, and to block harmful URLs and domain names.</p><p>The MHRA works to prevent false customer feedback from promoting illegal online suppliers and has arrangements in place with major search engine providers to delist offending domain names. The MHRA also works with payment providers to disrupt the processing of payments via illegal sites. The MHRA will take appropriate enforcement action, including, where necessary, prosecuting those who put public health at risk.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/11/2023 13:00:15 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1672415

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes and Obesity: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has held discussions with the MHRA on preventing unlicensed online (a) marketing and (b) sale of second generation GLP-1 weight management medications.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	3294
answer	answer is ministerial correction date of answer 01/12/2023 answer text <p>The Department and the Medicines and Healthcare products Regulatory Agency (MHRA) are members of the GLP1-RA Incident Management Team. Risk management in relation to the advertising and sale of these medicinal products is a standing item for discussion.</p><p>MHRA is obliged to consider complaints received about the advertisement of prescription-only medicines (POMs) to the public. Advertising investigations are carried out on a case-by-case basis, having regard to the circumstances of the particular case. Completed advertising investigations leading to correction of advertising materials are available at the following link:</p><p><a href="https://www.gov.uk/government/collections/advertising-investigations-by-mhra" target="_blank">https://www.gov.uk/government/collections/advertising-investigations-by-mhra</a></p><p>MHRA works closely with other regulators to help ensure that the public are protected from the advertising of POMs. A joint enforcement operation is in place with the Advertising Standards Authority to take targeted action against weight-loss treatment providers who use social media to promote POMs.</p><p>MHRA takes proportionate action, on a case-by-case basis, to enforce the Human Medicines Regulations 2012 in respect of the advertisement, sale, and supply of second-generation glucagon-like peptide 1 weight management medications. In cases of serious non-compliance, this can include undertaking formal criminal investigations and, where appropriate and evidentially supported, prosecution through the Crown Prosecution Service.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 3292 question first answered 01/12/2023 14:01:16 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day